A new paper authored by the LDN Trial team has been published in the scientific journal British Medical Journal, entitled “Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia” The paper outlines the protocol for the LDN Clinical Trial which will assess the efficacy of low dose naltrexone (LDN) for improving fatigue and other related symptoms in individuals with Post-COVID Fatigue Syndrome (PCFS).